LGL Partners LLC Invests $500,000 in Liquidia Corporation $LQDA

LGL Partners LLC purchased a new position in Liquidia Corporation (NASDAQ:LQDA) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,500 shares of the company’s stock, valued at approximately $500,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Liquidia by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock worth $556,000 after buying an additional 1,700 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Liquidia by 10.7% in the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock worth $12,703,000 after buying an additional 82,955 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Liquidia by 15.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after buying an additional 16,022 shares during the period. Creative Planning raised its holdings in shares of Liquidia by 40.7% in the second quarter. Creative Planning now owns 26,840 shares of the company’s stock worth $334,000 after buying an additional 7,765 shares during the period. Finally, Legal & General Group Plc raised its holdings in shares of Liquidia by 13.4% in the second quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock worth $1,174,000 after buying an additional 11,111 shares during the period. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Price Performance

Shares of NASDAQ:LQDA opened at $60.98 on Tuesday. Liquidia Corporation has a 52-week low of $11.85 and a 52-week high of $62.30. The stock has a market cap of $5.42 billion, a P/E ratio of 435.60 and a beta of 0.41. The business’s 50 day moving average is $42.53 and its 200 day moving average is $37.56. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company had revenue of $132.87 million for the quarter, compared to analysts’ expectations of $119.44 million. The company’s revenue for the quarter was up 4187.1% on a year-over-year basis. Sell-side analysts predict that Liquidia Corporation will post 2.97 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on LQDA. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a report on Thursday, March 5th. Wells Fargo & Company increased their price target on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Finally, HC Wainwright increased their price target on Liquidia from $55.00 to $67.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Liquidia currently has an average rating of “Moderate Buy” and an average price target of $49.33.

Insider Buying and Selling

In related news, CEO Roger Jeffs sold 32,744 shares of the stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $38.37, for a total value of $1,256,387.28. Following the transaction, the chief executive officer owned 1,137,599 shares of the company’s stock, valued at $43,649,673.63. This represents a 2.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Stephen M. Bloch sold 318,893 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $50.23, for a total value of $16,017,995.39. Following the completion of the transaction, the director directly owned 1,870,042 shares in the company, valued at approximately $93,932,209.66. This trade represents a 14.57% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,047,713 shares of company stock valued at $46,156,003 over the last quarter. 25.60% of the stock is owned by corporate insiders.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).